CoreWeave Stock Extends A 5-Day Losing Streak To A 19% Loss
A five-day slide in the tech name puts its underlying financial health back in focus.
A five-day slide in CoreWeave (CRWV) stock has erased about $11 billion from the company’s market value. The stock has now moved lower for 5 consecutive trading days, shedding a cumulative 19% over that period and leaving its market capitalization at about $48 billion.
For anyone holding the shares, this streak accounts for nearly all of the stock’s net three-month decline. The move has been specific to the company; over the same 5 trading days the S&P 500 returned -1.2%.
How The Streak Stacks Up Against The S&P 500
- Rocket Lab Stock Slides 17% Over 5 Straight Down Days
- A 5-Day Losing Streak Has Corning Stock Down 16%
- How Will Salesforce Stock React To Its Upcoming Earnings?
- Amkor Technology Stock: 5 Straight Red Days, Down 22%
- A 5-Day Losing Streak Has Credo Technology Stock Down 21%
- How Will CrowdStrike Stock React To Its Upcoming Earnings?
Here is how CRWV stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | CRWV | S&P 500 |
|---|---|---|
| 1D | -1.8% | -0.3% |
| 5D (Current Streak) | -18.6% | -1.2% |
| 1M (21D) | 20.0% | 3.2% |
| 3M (63D) | -18.2% | 2.4% |
| YTD 2026 | 20.4% | 11.8% |
| 2025 | 16.4% | |
| 2024 | 23.3% | |
| 2023 | 24.2% |
The stock’s slide aligns with strained fundamentals.
The market may be weighing a mixed financial picture. While revenue over the last twelve months grew 115.3%, far outpacing the S&P 500 median revenue growth of 8.4%, profitability remains elusive. CoreWeave’s operating margin over the last twelve months is -3.0%, standing in contrast to an S&P 500 median of 18.4%.
Further, the company has negative trailing earnings, which means it does not have a meaningful price-to-earnings multiple. This combination of rapid growth with a lack of profitability can draw scrutiny when market sentiment shifts.
A streak is a signal to check the underlying business.
A streak of this length is information, not an instruction. It tells you that a stock has momentum and the market’s attention, but it does not tell you whether the price is right. The disciplined move is to treat the streak as a prompt to re-evaluate.
The numbers here provide a starting point for that work: weighing the company’s high growth against its current lack of profits. The question is always whether the business you see justifies the price you are being asked to pay for it.
If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.